EP Patent

EP1827385A2 — Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject

Assigned to Adamas Pharmaceuticals Inc · Expires 2007-09-05 · 19y expired

What this patent protects

The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g. memantine) to a subject.

USPTO Abstract

The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g. memantine) to a subject.

Drugs covered by this patent

amantadine-hydrochloride (AMANTADINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP1827385A2
Jurisdiction: EP
Classification: —
Expires: 2007-09-05
Drug substance claim: No
Drug product claim: No
Assignee: Adamas Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.